MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.
You may also be interested in...
China’s HEC Pharm, the last ANDA filer for fingolimod standing in patent litigation, has won a key invalidity challenge against a dosing-regimen patent shielding the multiple sclerosis treatment. However, the Federal Circuit was split on whether it had applied a heightened standard for negative claim limitations.
In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.
Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.